TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04609033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: instillation of local anaesthetic in the abdominal cavity at the end of the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: instillation of local anaesthetic in the abdominal cavity at the end of the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + morphine
Description: instillation of local anaesthetic + morphine sulfate in the abdominal cavity at the end of the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + morphine + ketamine
Description: instillation of local anaesthetic + morphine sulfate + ketamine in the abdominal cavity at the end of the procedure
Study: NCT02096523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection for platelet protein samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection for platelet protein samples
Study: NCT02306759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.3mg/kg in 50ml normal saline, administered over 15 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 50ml, administered over 15 minutes
Study: NCT03661411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 100mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75mg
Description: 75mg（after first dose of 300mg）qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Iv at 0.9 milligrams per kilogram (mg/kg)
Study: NCT02329054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group C: daily dosages will be adapted to their body weight.
Study: NCT02495025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based developmental screening and care coordination
Study: NCT03505112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Description: The patients in GDT group will receive intravenous crystalloid fluid or vasopressor or inotropic agent according to the goal-directed therapy protocol utilizing FloTrac / EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA).~After induction of anesthesia, the baseline stroke volume index (SVI) is measured and then 200-250 ml of crystalloid is administered over 5-10 minutes. If SVI increase by ≥10%, 200-250 ml of crystalloid is given repeatedly until the increase in SVI \<10%. If SVI does not increase by ≥10% and there is no decrease in mean arterial pressure (MAP), revaluate SVI every 10 minutes. Despite an increase in SVI of \<10% after fluid challenge, if a decrease in MAP is accompanied by cardiac index (CI) ≤ 2.5 L/min/m2, dobutamine is administered by continuous infusion. If there is a decrease in MAP but no decrease in CI, start low dose norepinephrine continuous infusion.
Study: NCT00336674

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal insulin
Description: 440IU Insulin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo insulin carrier solution containing benzalkonium chloride and glycerol
Study: NCT02112981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus Eluting Coronary Stent
Description: BioMimeTM Sirolimus Eluting Stent (CE Marked) has cobalt chromium NexGenTM platform (CE Marked) with Tamarin BlueTM balloon Delivery System (CE marked and with FDA clearance under 510k). Stent is coated with combination of Sirolimus drug and Biodegradable PLLA and PDLG polymers.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting Coronary stent
Description: Xience V/Xience Xpedition/Xience Prime stent is MULTI-LINK MINI VISION or MULTI-LINK VISION platform Cobalt chromium stent with Everolimus (active ingredient) embedded in a non-erodible polymer (inactive ingredient).
Study: NCT01391221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
Study: NCT02134587

Intervention type: OTHER
Group type: OTHER
Intervention: Multifaceted educational intervention
Description: 1. Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.~2. Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material~3. Distribution of educational material~4. Practical class to explain the correct fill of adverse drug events form~5. Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance.
Study: NCT02453685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Injected s.c./subcutaneously once daily with the largest meal Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected s.c./subcutaneously once daily at the same time every day, with the possibility of treatment intensification with insulin aspart (Basal-bolus arm) Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected s.c./subcutaneously once daily.
Study: NCT02622165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The REWARD serious game intervention
Description: The REWARD intervention is based on the dual process model incorporating strategies to influence both the automatic pathway (i.e., operant learning theory) and the conscious pathway (i.e., a focus on certain determinants). The central idea of the intervention will be that participants will earn credits in the game when scanning healthy (rather than unhealthy) snacks which will influence the advancement of the players in the game. This credit system will be related to the dietary quality index of the consumed snacks.
Study: NCT02925611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Study: NCT01625351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Patients receive alemtuzumab on days -14 through -12 (Day 0 = stem cell transplantation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Patients receive fludarabine phosphate on days -11 through -7. (Day 0 = stem cell transplantation.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Patients receive sirolimus beginning on day -1 with taper beginning on day 90. (Day 0 = stem cell transplantation.)~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Patients receive busulfan on days -6 through -3. (Day 0 = stem cell transplantation.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Patients receive melphalan on days -2 and -1. (Day 0 = stem cell transplantation.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cells
Description: Patients undergo CD3 depleted haploidentical hematopoietic stem cell transplant (HSCT) on day 0. Patients also undergo CD45RA depleted HSCT infusion on day 1. (Day 0 = stem cell transplantation.)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study: NCT03345498

Intervention type: DRUG
Intervention: Entecavir
Description: Entecavir is the antiviral drug of choice recommended for hepatitis B virus treatment in presence of decompensated cirrhosis

Intervention type: DRUG
Intervention: Entecavir
Description: Entecavir is the antiviral drug of choice recommended for hepatitis B virus treatment in presence of decompensated cirrhosis
Study: NCT03371875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated transition care reminders
Description: The CHICA system will gather the elements of the TRAQ questionnaire and report the specific areas of deficiency to the physician. If a patient reaches the point of care transition (18 years), then an automated email is sent to a clinic nurse.
Study: NCT01821261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouth Rinse 19668-012
Description: 20 ml of experimental mouth rinse 19668-012 for 30 seconds, twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mouth Rinse 500347078842
Description: 10 ml of mouth rinse 500347078842 for 60 seconds, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste 035000513007
Description: Approximately one inch of toothpaste 035000513007, twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste 035000513007
Description: Approximately one inch of toothpaste 035000513007, twice daily
Study: NCT06059170

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LARS score/ EORTC QLQ C30
Description: administering questionnaire
Study: NCT01144910

Intervention type: OTHER
Intervention: methacholine challenge test
Description: 2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
Study: NCT01821261

Intervention type: DRUG
Group type: OTHER
Intervention: Toothpaste 035000513007
Description: Approximately one inch of toothpaste 035000513007, twice daily
Study: NCT01542606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NORMA-SENSE
Description: The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
Study: NCT04881006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg tablets
Description: Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Farxiga® 10 mg tablets
Description: Manufactured by AstraZeneca Pharmaceuticals LP
Study: NCT02571517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Patients assigned to experimental group (group 1) will receive iv methylprednisolone 2 mg/kg/day (divided in two doses) doses and/or oral prednisolone 2,5 mg/kg/day (divided in two doses) during 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients assigned to control group (group 2) will receive iv/oral glucose 5% solution as placebo, 2 mg/kg/day (divided in two doses) during 7 days.
Study: NCT04980118

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: A nutritional intervention program that consisted of two individual nutritional consults.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity group
Description: A nutritional and physical activity intervention program that consisted of two individual nutritional consults and five nutritional group lectures.
Study: NCT01132456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent treatment
Description: Endeavor RESOLUTE Zotarolimus-Eluting Coronary Stent Implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent treatment
Description: Endeavor RESOLUTE Zotarolimus-Eluting Coronary Stent Implantation
Study: NCT03508895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole hemp seed protein
Description: The intervention was provided in the form of a smoothie.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole hemp seed protein plus bioactive peptides
Description: The intervention was provided in the form of a smoothie.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Casein protein
Description: The intervention was provided in the form of a smoothie.
Study: NCT04263870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: oral capecitabine 1000mg per m2 bid d1-14, intravenous oxaliplatin 130mg d1 per m2, sintilimab 200mg (every 3 weeks)
Study: NCT02856256

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RedBull® energy drink
Description: Subjects consume 25 mL of RedBull® energy drink
Study: NCT03689296

Intervention type: OTHER
Intervention: Questionnaires (Phase 3)
Description: * CardioVascular Risk (CVR) questionnaire representation~* SF12~* Getting Better My Way~* My recovery plan~* Psycom~* Partner In Health scale

Intervention type: OTHER
Intervention: Focus groups (Phase 2)
Description: Focus group interviews conducted by two health sociologists in 4 distinct categories: caregivers, patients, primary health care professionals and psychiatric professionals.

Intervention type: OTHER
Intervention: Focus groups (Phase 2)
Description: Focus group interviews conducted by two health sociologists in 4 distinct categories: caregivers, patients, primary health care professionals and psychiatric professionals.

Intervention type: OTHER
Intervention: Focus groups (Phase 2)
Description: Focus group interviews conducted by two health sociologists in 4 distinct categories: caregivers, patients, primary health care professionals and psychiatric professionals.

Intervention type: OTHER
Intervention: Focus groups (Phase 2)
Description: Focus group interviews conducted by two health sociologists in 4 distinct categories: caregivers, patients, primary health care professionals and psychiatric professionals.

Intervention type: OTHER
Intervention: semi-structured interviews (Phase 1)
Description: Conduct of exploratory semi-directive interviews with users, caregivers, primary health care professionals and psychiatric professionals by a health sociologist

Intervention type: OTHER
Intervention: semi-structured interviews (Phase 1)
Description: Conduct of exploratory semi-directive interviews with users, caregivers, primary health care professionals and psychiatric professionals by a health sociologist
Study: NCT02252393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intraoperative complication management/prevention
Description: Undergo RARC with EUD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03157609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermometry
Description: Within the same patient comparison of 2 thermometry methods: SpotOn skin sensor versus oesophageal temperature probe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermometry
Description: Within the same patient comparison of 2 thermometry methods: SpotOn skin sensor versus oesophageal temperature probe
Study: NCT01507805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EA preconditioning
Description: EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)with electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham EA preconditioning
Description: Patients in Sham EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)without electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
Study: NCT02792465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study: NCT03295487

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-O
Description: transobturator tape has been applied to all the patients in the study,and local estrogen vaginal cream is only applied to patients in group A

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-O
Description: transobturator tape has been applied to all the patients in the study,and local estrogen vaginal cream is only applied to patients in group A
Study: NCT04207827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: xSmoker app
Description: xSmoker - mHealth intervention consisted of using the app xSmoker

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: xSmoker app
Description: xSmoker - mHealth intervention consisted of using the app xSmoker

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Text messages with content based on the Motivation and Problem Solving approach and informed by our prior work.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual postnatal care
Study: NCT00686881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (PegIFN-2b)
Description: PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Stronger neo minophagen C (SNMC)
Description: SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
Study: NCT00789087

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Videothoracoscopic talc poudrage (VT).
Description: Videothoracoscopic talc poudrage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Talc slurry through a chest tube (DT).
Description: Talc slurry through a chest tube
Study: NCT00769548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Drug used for TAS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Drug used for TAS.
Study: NCT03127735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1436032
Description: BAY1436032 administered continuously as a single agent dosed twice a day orally on Days 1 to 28 of a 28-day cycle.~Patients may continue treatment with BAY1436032 until disease progression, development of other unacceptable toxicity or Investigator discretion.
Study: NCT03322761

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Systematic exercise training
Description: Combination of standard medical treatment and systematic early exercise training in persons with MS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: Informations regarding health benefits of physical activity and exercise.
Study: NCT06389903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: assessment
Description: post-surgery behavioral assessment using scales
Study: NCT02547389

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community support group

Intervention type: OTHER
Group type: OTHER
Intervention: Printed material Supported
Study: NCT02788409

Intervention type: OTHER
Intervention: Not applicable for study
Description: Provide external perspective on background second primary cancer incidence rates for REASSURE study.
Study: NCT03243669

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High-definition
Description: High-definition colonoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High-definition
Description: High-definition colonoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High-definition
Description: High-definition colonoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High-definition
Description: High-definition colonoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High-definition
Description: High-definition colonoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High-definition
Description: High-definition colonoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Virtual chromoendoscopy
Description: Virtual chromoendoscopy
Study: NCT00769548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Drug used for TAS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Drug used for TAS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Drug used for TAS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Drug used for TAS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Drug used for TAS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Drug used for TAS.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Description: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Description: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Description: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Description: radiation therapy
Study: NCT04341506

Intervention type: DEVICE
Intervention: Non-contact ECG
Description: A non-contact ECG will be used to detect a patient cardiac electrical activity.
Study: NCT01299948

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: 5 mg prednisolone orally per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 5 mg prednisolone orally per day
Study: NCT03689296

Intervention type: OTHER
Intervention: semi-structured interviews (Phase 1)
Description: Conduct of exploratory semi-directive interviews with users, caregivers, primary health care professionals and psychiatric professionals by a health sociologist

Intervention type: OTHER
Intervention: semi-structured interviews (Phase 1)
Description: Conduct of exploratory semi-directive interviews with users, caregivers, primary health care professionals and psychiatric professionals by a health sociologist